[go: up one dir, main page]

WO2002004645A3 - A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas - Google Patents

A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas Download PDF

Info

Publication number
WO2002004645A3
WO2002004645A3 PCT/EP2001/008094 EP0108094W WO0204645A3 WO 2002004645 A3 WO2002004645 A3 WO 2002004645A3 EP 0108094 W EP0108094 W EP 0108094W WO 0204645 A3 WO0204645 A3 WO 0204645A3
Authority
WO
WIPO (PCT)
Prior art keywords
pancreas
heart
skeletal muscle
splice variants
predominant expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/008094
Other languages
French (fr)
Other versions
WO2002004645A2 (en
Inventor
Guido David
Joachim Duerr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Priority to AU2001287610A priority Critical patent/AU2001287610A1/en
Publication of WO2002004645A2 publication Critical patent/WO2002004645A2/en
Publication of WO2002004645A3 publication Critical patent/WO2002004645A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the field of carbohydrates and more specifically to the field of heparan sulphate proteoglycans. A polynucleotide has been identified encoding heparanase activity. This is the second gene encoding heparanase catalytic activity which is identified in humans. Several splice variants of said gene have been identified with a specific expression pattern in skeletal muscle, heart and pancreas.
PCT/EP2001/008094 2000-07-12 2001-07-12 A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas Ceased WO2002004645A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001287610A AU2001287610A1 (en) 2000-07-12 2001-07-12 A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202442.0 2000-07-12
EP00202442 2000-07-12

Publications (2)

Publication Number Publication Date
WO2002004645A2 WO2002004645A2 (en) 2002-01-17
WO2002004645A3 true WO2002004645A3 (en) 2002-10-17

Family

ID=8171776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008094 Ceased WO2002004645A2 (en) 2000-07-12 2001-07-12 A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas

Country Status (2)

Country Link
AU (1) AU2001287610A1 (en)
WO (1) WO2002004645A2 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043830A2 (en) * 1998-02-24 1999-09-02 Pharmacia & Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2000003036A1 (en) * 1998-07-10 2000-01-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
WO2001000643A2 (en) * 1999-06-25 2001-01-04 Insight Strategy & Marketing Ltd. Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase
WO2001021814A1 (en) * 1999-09-23 2001-03-29 Merck Patent Gmbh Heparanase-2, a member of the heparanase protein family
WO2001046392A2 (en) * 1999-12-22 2001-06-28 Oxford Glycosciences (Uk) Ltd. Homologues of human heparanase and splice variants thereof
WO2001048161A2 (en) * 1999-12-23 2001-07-05 Schering Aktiengesellschaft Human heparanase-related polypeptide and nucleic acid
WO2001077341A2 (en) * 2000-04-11 2001-10-18 Janssen Pharmaceutica N.V. Mammalian heparanase
WO2001079253A1 (en) * 2000-04-18 2001-10-25 Human Genome Sciences, Inc. Extracellular matrix polynucleotides, polypeptides, and antibodies
WO2001081569A2 (en) * 2000-04-20 2001-11-01 Pharmacia & Upjohn Company Heparanase ii, a human heparanase paralog

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043830A2 (en) * 1998-02-24 1999-09-02 Pharmacia & Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2000003036A1 (en) * 1998-07-10 2000-01-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
WO2001000643A2 (en) * 1999-06-25 2001-01-04 Insight Strategy & Marketing Ltd. Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase
WO2001021814A1 (en) * 1999-09-23 2001-03-29 Merck Patent Gmbh Heparanase-2, a member of the heparanase protein family
WO2001046392A2 (en) * 1999-12-22 2001-06-28 Oxford Glycosciences (Uk) Ltd. Homologues of human heparanase and splice variants thereof
WO2001048161A2 (en) * 1999-12-23 2001-07-05 Schering Aktiengesellschaft Human heparanase-related polypeptide and nucleic acid
WO2001077341A2 (en) * 2000-04-11 2001-10-18 Janssen Pharmaceutica N.V. Mammalian heparanase
WO2001079253A1 (en) * 2000-04-18 2001-10-25 Human Genome Sciences, Inc. Extracellular matrix polynucleotides, polypeptides, and antibodies
WO2001081569A2 (en) * 2000-04-20 2001-11-01 Pharmacia & Upjohn Company Heparanase ii, a human heparanase paralog

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EMBL; 18 October 1999 (1999-10-18), HATTORI M ET AL.: "Homo sapiens genomic DNA, 21q region, clone: B2289H10 A012(-21)", XP002155089, Database accession no. AG019564 *
DATABASE EMBL [online] EMBL; 28 October 1998 (1998-10-28), STRAUSBERG R: "qg97h02.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1843155 3', mRNA sequence", XP002155088, Database accession no. AI222323 *
KOSIR M A ET AL.: "Degradation of basement membrane by prostate tumor heparanase", JOURNAL OF SURGICAL RESEARCH, vol. 81, no. 1, January 1999 (1999-01-01), pages 42 - 47, XP002155606 *
KOSIR MA ET AL.: "Human prostate carcinoma cells produce extracellular heparanase", JOURNAL OF SURGICAL RESEARCH, vol. 67, no. 1, January 1997 (1997-01-01), pages 98 - 105, XP002155605 *
MCKENZIE E ET AL.: "Cloning and expression profiling of hpa2, a novel mammalian heparanase family member", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 276, no. 3, 5 October 2000 (2000-10-05), pages 1170 - 1177, XP002155087 *

Also Published As

Publication number Publication date
WO2002004645A2 (en) 2002-01-17
AU2001287610A1 (en) 2002-01-21

Similar Documents

Publication Publication Date Title
EP2333099A3 (en) Enzymes having alpha amylase activity and methods of use thereof
IS7663A (en) Functional heart muscle cells from human embryonic stem cells
AU2003297356A8 (en) Prevention and treatment of cardiac arrhythmias
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
MXPA02003724A (en) Treatment of fatigue, head injury and stroke.
AU2002352443A1 (en) Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
DE60114969D1 (en) Prediction of arrhythmia based on changes in morphology of intracardiac ECG signals
DE69634655D1 (en) Use of a physiologically functional food to improve and / or strengthen brain function, learning ability and memory function
AU2002361811A8 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2008024768A3 (en) Electrocardiograph and blood pressure signals simulator
WO2002066500A3 (en) ANTAGONISTS FPR Α4β7-INTEGRIN
AU2756701A (en) Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
WO2002004645A3 (en) A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas
DE69929192D1 (en) HEART STIMULATOR WITH DETERMINATION OF THE STIMULATION THRESHOLD
SI1572180T1 (en) Use of alpha-phenylthiocarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity
WO2003065046A3 (en) Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
AU2003218339A8 (en) Immune modulatory activity of human ribonucleases
ITRM20030596A1 (en) USE OF INHIBITORS OF LONG PTX3 PENTRAXINE, FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES WHICH REPLY TO THE INHIBITION OF THE BIOLOGICAL ACTIVITY OF ITS PTX3.
HUP0100044A3 (en) Modified antisense nucleotides complementary to a section of the human ha-ras gene
WO2002056837A3 (en) Inhibition of protein-phosphatases for the treatment of heart failure
IL172416A0 (en) Modified human acid sphingomyelinase having increased activity, and methods for making the same
CN2476983Y (en) Health massage gloves
PL365565A1 (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
MXPA00012560A (en) Use of interleukin-11 to treat gastrointestinal disorders.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP